EVOLUS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
EVOLUS, INC. (EOLS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $752.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-03
- EVOLUS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $752.00K, a 76.29% decline from fiscal 2024.
- EVOLUS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $3.17M, a 2231.62% increase from fiscal 2023.
- EVOLUS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $136.00K, a 147.27% increase from fiscal 2022.
- EVOLUS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $55.00K, a 72.50% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2025-12-31 | $752.00K 10-K · filed 2026-03-03 |
| 2024-12-31 | $3.17M 10-K · filed 2026-03-03 |
| 2023-12-31 | $136.00K 10-K · filed 2026-03-03 |
| 2022-12-31 | $55.00K 10-K · filed 2023-03-08 |
| 2021-12-31 | $200.00K 10-K · filed 2023-03-08 |
| 2020-12-31 | $0.00 10-K · filed 2021-03-25 |
| 2019-12-31 | $2.31M 10-K · filed 2021-03-25 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |